Genitourinary Cancers | Specialty

Second-Line Angiogenesis Inhibition in mRCC

March 19th 2014

Second-Line Treatment of Metastatic Renal Cell Carcinoma

March 19th 2014

Optimizing the Upfront Treatment of mRCC

March 19th 2014

Cytoreductive Nephrectomy in Untreated Metastatic RCC

March 19th 2014

Frontline Treatment of Poor-Risk mRCC

March 19th 2014

Treatment of Metastatic Non-Clear Cell RCC

March 19th 2014

Introduction: Multidisciplinary Frontline Treatment of mRCC

March 19th 2014

Dr. Charles Ryan on Prescribing Preferences

March 13th 2014

Charles Ryan, MD, discusses community oncologist prescribing preferences for patients with prostate cancer or renal cell carcinoma.

Exceptional Responder Provides Treatment Clues in Bladder Cancer

March 13th 2014

An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib.

Dr. Plimack on an mTOR/HDAC Inhibitor Combination in RCC

March 11th 2014

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial that looked at overcoming mTOR resistance with an HDAC inhibitor in renal cell carcinoma (RCC).

Dr. Figlin on Intermediate Prognosis Patients With mRCC

March 5th 2014

Robert Figlin, MD, FACP, discusses an analysis of the heterogeneity of intermediate prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.

Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBC

March 3rd 2014

A review by André P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.

Dr. McDermott on Targeting PD-1/PD-L1 in Kidney Cancer

February 28th 2014

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of targeting PD-1 or PD-L1 in patients with kidney cancer

Some With Micropapillary Urothelial Carcinoma May Benefit From HER2-Targeted Treatment

February 27th 2014

Some patients with micropapillary urothelial carcinoma face a three-fold risk of cancer death because their disease amplifies HER2 and overexpresses its protein product, and there may be a role for treatment of the condition with HER2- targeted agent trastuzumab, which has vastly increased the odds of survival for eligible patients with breast cancer.

At Issue: IMRT Self-Referral

February 14th 2014

A study published in the New England Journal of Medicine sparked controversy and criticism when it claimed that many men received unnecessary radiation therapy for their prostate cancer due to self-referral.

Dr. Rini on Barriers to Optimal Care of RCC

February 14th 2014

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC).

Built for the Long Haul: Michigan Institute of Urology Offers Reliable Care in Turbulent Times

February 13th 2014

An inside look at how the Michigan Institute of Urology is navigating the shifting healthcare and civic landscape.

Dr. Tannir on Sunitinib Plus Temsirolimus for mRCC

February 12th 2014

Nizar M. Tannir, MD, FACP, from The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.

Dr. Balar on Bevacizumab in Bladder Cancer

February 4th 2014

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses two trials that evaluate the efficacy of bevacizumab in bladder cancer.

PD-L1 Expression Independent Prognostic Indicator in mRCC

February 3rd 2014

High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.